IMR Press / EJGO / Volume 21 / Issue 1 / pii/2000119

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?

Show Less
1 Division of Medical Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy
Eur. J. Gynaecol. Oncol. 2000, 21(1), 84–85;
Published: 10 February 2000

A phase I study was performed in order to evaluate the tolerability of the combination of fixed doses of carboplatin and pacli­taxel and escalated doses of topotecan as first line chemotherapy for advanced epithelial ovarian cancer. Three stage III and one stage IV patients entered the study. The dose limiting toxicity (neutropenia and thrombocytopenia) was reached at the first dose level: paclitaxel 175 mg/m2 on day I, carboplatin AUC 5 on day l and topotecan 0.5 mg/m2 daily from day 1 to day 3. We con­clude that it is not possible to add topotecan to standard regimens of carboplatin and paclitaxel without bone marrow support.

Ovarian cancer
Back to top